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Abstract
Objective: Distal sensory polyneuropathy (DSP) and neuropathic pain are
important clinical concerns in virally suppressed people with HIV. We deter-
mined how these conditions evolved, what factors influenced their evolution, and
their clinical impact. Methods: Ambulatory, community-dwelling HIV seroposi-
tive individuals were recruited at six research centers. Clinical evaluations at base-
line and 12 years later determined neuropathy signs and distal neuropathic pain
(DNP). Additional assessments measured activities of daily living and quality of
life (QOL). Factors potentially associated with DSP and DNP progression
included disease severity, treatment, demographics, and co-morbidities. Adjusted
odds ratios were calculated for follow-up neuropathy outcomes. Results: Of 254
participants, 21.3% were women, 57.5% were non-white. Mean baseline age was
43.5 years. Polyneuropathy prevalence increased from 25.7% to 43.7%. Of 173
participants initially pain-free, 42 (24.3%) had incident neuropathic pain. Base-
line risk factors for incident pain included unemployment (OR [95% CI], 5.86
[1.97, 17.4]) and higher baseline body mass index (BMI) (1.78 [1.03, 3.19] per
10-units). Participants with neuropathic pain at follow-up had significantly worse
QOL and greater dependence in activities of daily living than those who remained
pain-free. Interpretation: HIV DSP and neuropathic pain increased in prevalence
and severity over 12 years despite high rates of viral suppression. The high burden of
neuropathy included disability and poor life quality. However, substantial numbers
remained pain-free despite clear evidence of neuropathy on exam. Protective factors
included being employed and having a lower BMI. Implications for clinical practice
include promotion of lifestyle changes affecting reversible risk factors.
Introduction
Despite considerable research prior to the development of
virally suppressive combination antiretroviral therapy
(cART) regimens, comparatively little is known about the
longitudinal evolution over a decade or more of distal
sensory polyneuropathy (DSP) and neuropathic pain in
virally suppressed older people with HIV (PWH), and
what clinical factors influence this evolution. Notably, not
all those with DSP have neuropathic pain, and whether
these individuals will go on to develop it despite viral
suppression is unknown.
The clinical impact of DSP is substantial. In previous
cross-sectional studies, distal neuropathic pain (DNP) in
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HIV-DSP is associated with opioid use, depression, and
low quality of life (QOL).1-4 Sensory neuropathy is a
major contributor to balance difficulties and falls. In one
study, of 3379 PWH and HIV negative (HIV) adults,
balance problems were more common in those with
DSP.5 DNP is often treatment-resistant.6
This study sought to characterize the longitudinal evo-
lution of DSP and DNP, evaluate predictors of these con-
ditions and describe their impact on QOL over a 12-year
follow-up. The CHARTER Aging cohort, which enrolled
individuals shortly after the roll-out of effective cART
and brought them back 12 years later, provided a unique
opportunity to assess these issues.
Methods
Participants
The participants underwent standardized clinical and labora-
tory evaluations at baseline and 12-year follow-up at six
U.S. centers. Initial visits took place between 2003 and 2007,
and follow-up assessments between 2016 and 2019. Evalua-
tions included clinical examination for neuropathy signs (bi-
lateral distal vibration, sharp, and touch loss) and self-
reported neuropathy symptoms (pain, numbness, paresthe-
sias). Moderate or worse neuropathy was defined as two or
more clinical signs of neuropathy from the list above. DNP
was defined as burning, aching, or shooting symptoms and
classified into five categories of clinician-rated pain severity:
none, slight (occasional, fleeting), mild (frequent), moderate
(frequent, disabling), and severe (constant, daily, disabling,
requiring analgesic medication or other pain medication).
All participants signed an IRB-approved written consent.
Laboratory evaluations
HIV disease was diagnosed by enzyme-linked immunosor-
bent assay with Western blot confirmation. HIV viral load
in plasma was measured using commercial assays and
deemed undetectable at a lower limit of quantitation of
50 copies/mL. CD4 was measured by flow cytometry and
nadir CD4 was assessed by self-report. Urine toxicology was
assessed including detection of opioids and cannabis.
Other clinical evaluations
Factors potentially associated with DSP and DNP progres-
sion included HIV disease severity (nadir and current
CD4+ cell counts), ART including cumulative exposure to
neurotoxic ynucleoside antiretrovirals, zalcitabine (ddC),
didanosine (ddI), and stavudine (d4T); aka “d-drugs”),
self-reported employment, body mass index (BMI) and
diabetes (self-report and use of anti-diabetic medications)
(Table 1). Use of opioids was determined by urine toxicol-
ogy, as noted above. The Medical Outcomes Study HIV
Health Survey (MOSHIV) has been shown to be a reliable
and valid tool for assessing overall QOL, daily functioning,
and physical health.7,8 The MOS-HIV contains 36 ques-
tions that assess physical and mental dimensions of health.
These are scored as summary percentile scales ranging from
0 to 100, with higher scores indicating better health. Cur-
rent mood was assessed by the Beck Depression Inventory
(BDI) II.9 Dependence in instrumental activities of daily
living (IADLs) was assessed with a modified version of the
Lawton and Brody Scale10 that asks participants to rate
their current and best lifetime levels of independence for 13
major IADLs such as shopping, financial management,
transportation, and medication management.11 An
employment questionnaire asked about job loss, decreases
in work productivity, accuracy, and quality; increased effort
required to do one’s usual job; and increased fatigue with
the usual workload. Major depressive disorder (MDD) was
diagnosed using the CIDI.12
Statistical analyses
Group differences on background characteristics (i.e.,
demographics, neuropsychiatric, and neuromedical charac-
teristics) were examined using analysis of variance, Wil-
coxon/Kruskal–Wallis tests, and Chi-square statistics as
appropriate. Odds ratios were calculated for the association
of baseline variables to follow-up neuropathy outcomes.
We used multivariable linear regression models to test
interaction effects. In the absence of an interaction, additive
effects were tested. Analyses were conducted using JMP
Pro version 15.0.0 (SAS Institute Inc., Cary, NC, 2018).
Results
Baseline visits were between 2003 and 2007 and follow-up
visits were between 2013 and 2019. Table 2 presents the
demographic and clinical characteristics of the study par-
ticipants at their baseline visits. Of the 254 participants,
Women comprised 54 (21.3%) and non-whites 152
(57.5%). Mean baseline age was 43.5 (8.01) years and
median (interquartile range) nadir and current CD4 were
178 (IQR 29, 294) and 446 (282, 607), respectively. The
number using combination ART increased from 191
(75.2%; 95% CI 69.5, 80.1) at baseline to 245 (96.5%;
93.4, 98.1) at follow-up (during the interval, ART initia-
tion guidelines changed to include all PWH). Viral sup-
pression improved from 47.6% at baseline to 82.4% at
follow-up. Moderate or worse DSP (2 or more signs)
increased from 65/253 (25.7%) at baseline to 110/253
(43.7%) at 12 years; 60 individuals (32.1%) had incident
(new onset) DSP. DSP remitted in 14 (5.57%). Of 173
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individuals without pain at baseline 42 (24.3%) had inci-
dent DNP. Of 80 with DNP at baseline, 23 (28.8; 95% CI
[20.0, 39.5]) worsened (at least one grade higher) at
12 years. In the subset of 106 individuals never exposed
to neurotoxic d-drugs, the proportion with DSP increased
from 14.2% to 34.0%. In the same subset, of 81 without
baseline DNP, 17 (21.0%) had incident DNP.
Figure 1 shows baseline predictors of incident DSP at
12-year follow-up. Significant predictors were older age
(OR 2.92 per decade [1.83, 4.86]), DNP (OR 3.93 [1.96,
8.02]) and height (OR 20.9 per cm [3.88, 128]). Non-sig-
nificant variables included sex, ethnicity, viral suppres-
sion, nadir and current CD4, diabetes mellitus,
cumulative d-drug exposure, BMI, employment, and life-
time alcohol abuse. Results were substantively similar for
those with viral suppression at 12 years. The odds of
developing moderate to severe incident neuropathy (2
signs) at 12 years increased by 2.59 (1.39, 4.89) for those
with 1 sign of DSP at baseline, compared to those with
no signs. For those with DNP at baseline, the odds of
incident DSP were higher 3.92 (1.97, 7.94) compared to
no DNP at baseline. The odds of incident DSP increased
in rough proportion to the severity of DNP at baseline,
from 3.84 (1.62, 9.09) for those with mild pain to 6.59
(1.16, 37.5) for those with severe pain. In a multivariable
logistic regression that included each of the significant
univariable predictors, age (OR 2.80 per decade [1.69,
4.83]), DNP (OR 4.03 [1.86, 8.98]) and height (OR 1.53
per cm [1.19, 2.0]) remained significant predictors. In the
Table 1. Key predictor and outcome variable definitions.
Outcomes
Moderate or
worse DSP
2 or more signs: distal, symmetrical reduction or
loss of vibration, pin or ankle reflexes
DNP Distal, symmetrical pain with neuropathic quality
Incident DSP DSP at follow-up in a participant without DSP at
baseline
Incident DNP DNP at follow-up in a participant without DNP at
baseline
Worsened DNP An increase in DNP of at least one grade in a
participant with DNP at baseline
Incident or
worse DNP
Either incident DNP or worsened DNP
Incident MDD MDD at follow-up in a participant who did not
meet MDD criteria at baseline
Mood Beck Depression Inventory (BDI) scores
IADLs Lawton and Brody Scale instrumental activities of
daily living
Quality of life Medical Outcomes Study HIV Health Survey
(MOSHIV)
Predictors
HIV disease
severity
Nadir and current CD4+ T cell counts
ART Cumulative exposure to neurotoxic nucleosides –
ddC, ddI, or d4T
Employment Self-reported employment
Obesity Body mass index (BMI)
Diabetes Self-report and use of anti-diabetic medications
DSP, distal sensory polyneuropathy; DNP, distal neuropathic pain;
MDD, major depressive disorder; IADLs, instrumental activities of daily
living; ART, antiretroviral therapy.
Table 2. Participant demographic and clinical characteristics at the baseline visit, by DSP and DNP status.
Characteristic All
DSP-free
(0/1 sign)
Mod to severe DSP
(≥2 signs) P
Pain-free with or
without DSP
DNP with or
without DSP P
N 253 188 65 173 80
Age, years (mean  SD) 43.5  8.01 41.8  7.33 48.4  7.94 0.0001 42.7  8.02 45.2  7.77 0.02
Education, years
(mean  SD)
13.1  2.54 13.1  2.62 13.4  2.32 0.422 13.1  2.49 13.2  2.68 0.79
Female sex, N (%) 54 (21%) 38 (20%) 16 (25%) 0.46 35 (20.2%) 19 (23.8%) 0.53
non-Hispanic white, N (%) 108 (42%) 81 (43%) 38 (59%) 0.82 70 (41%) 38 (48%) 0.29
CD4 nadir (cells/lL; median,
IQR)
178 (29,
294)
185 (40,
313)
120 (19, 220) 0.019 181 (27, 279) 150 (41, 298) 0.93
Current CD4 (median, IQR) 282 (446,
607)
452 (279,
641)
410 (314, 588) 0.803 440 (261, 634) 446 (336, 592) 0.28
On ART, N (%) 191 (75%) 132
(70.2%)
58 (89.2%) 0.001 128 (74%) 63 (78.8%) 0.41
Virally suppressed 120
(47.6%)
80 (42.8%) 40 (62.5%) 0.006 78 (45.4%) 42 (53.2%) 0.25
Cumulative d-drug years,
median (IQR)
0.049 (0,
36.9)
0 (0, 34.1) 14.5 (0, 42.7) 0.024 0 (0, 29.8) 12.5 (0, 46.2) 0.03
Body mass index
(mean  SD)
26.8  5.97 26.8  6.13 26.9  5.57 0.87 27.1  6.12 25.9  5.33 0.15
Employed, N (%) 72 (28.3%) 59 (31.4%) 13 (20.0%) 0.073 54 (31.2%) 18 (22.5%) 0.15
ART, antiretroviral therapy; DSP, distal sensory polyneuropathy; DNP, distal neuropathic pain. D-drug, neurotoxic nucleoside antiretroviral – zal-
citabine (ddC), didanosine (ddI), or stavudine (d4T).
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subset of PWH never exposed to neurotoxic d-drugs, sig-
nificant predictors were age (OR 3.28 per decade [1.60,
267]) and height (OR 2.40 [1.57, 4.00]).
Figure 2 shows baseline predictors of incident DNP at
12 years follow-up. Age (OR 4.50 [0.595, 34.7]) was sig-
nificantly associated with incident DNP; sex and ethnicity
were not. Height, viral suppression and nadir and baseline
CD4 did not predict incident DNP at follow-up
(Ps > 0.20). The presence of diabetes mellitus at baseline
did not predict incident DNP (1.01 [0.196, 5.18]). Higher
BMI was associated with incident DNP (OR 1.056 [1.00,
1.12] per unit increase in BMI). Individuals who were
employed at baseline were much less likely to have inci-
dent DNP at 12 years than those who were unemployed
(OR 0.166 [0.0561, 0.489]). Among those who already
had DNP at baseline, worsening was more likely in those
with lower CD4 nadir (OR 1.50 [1.09, 2.14] for every 100
cells decrease). Diabetes did not influence DNP worsening
(OR 2.01 [0.695, 5.83]) and none of the other predictor
variables was associated with DNP worsening. In a multi-
variable model with BMI and employment as predictors
of incident DNP, only being employed remained signifi-
cant (OR 0.186 [0.053, 0.501]). Forty of 80 (50%) PWH
with DNP at baseline had improved or absent DNP at
follow-up. Improved DNP was not related to age, sex,
ethnicity, BDI-II, employment, IADLs, nadir or current
CD4, viral suppression or BMI. In the subset of PWH
never exposed to neurotoxic d-drugs, no variables were
significant predictors of incident DNP.
Relationship of DNP at follow-up to
depressed mood and other clinically
relevant outcomes
PWH with DNP at follow-up had significantly higher
BDI-II scores than those without DNP (11.7  10.4 vs.
Figure 1. Univariate baseline predictors of incident DSP. DNP, distal neuropathic pain; BMI, body mass index. D-drug, neurotoxic nucleoside
antiretroviral – zalcitabine (ddC), didanosine (ddI), or stavudine (d4T).
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8.51  8.89, P = 0.0089) but differences in the propor-
tions with MDD were not significant (64.6% vs. 63.3%).
Participants whose DNP worsened had nonsignificantly
higher BDI-II scores than those who did not worsen
(13.8  2.87 vs. 10.158  9.76 P = 0.1631). Of 138 par-
ticipants who were independent in IADLs at baseline, 37
(26.8%) became dependent. Participants with DNP at fol-
low-up were more likely to have become dependent in
IADLs (OR 2.88 [1.30, 6.39]) and those with incident or
worsening DNP at follow-up were more likely to become
dependent (OR 2.31 [0.950, 5.61]). DSP status did not
influence IADL dependence (data not shown). Partici-
pants with DNP at V2 had significantly worse physical
and mental health MOS scores than those without
(39.1  12.1 vs. 48.2  10.8; P < 0.0001 and 46.8  13.1
vs. 52.4  9.6; P < 0.0002, respectively; Figure 3). PWH
with DNP were more likely to have positive urine
toxicology positive for opioids, in most cases prescribed
(OR 3.63 [1.48, 8.93]).
Discussion
Our findings highlight the high prevalence and increasing
burden of DSP and neuropathic pain in older long-term
PWH survivors despite viral suppression on ART. HIV
DSP and its symptoms worsened substantially with fol-
low-up over more than a decade. Even among those never
exposed to neurotoxic d-drugs, incident DNP occurred in
19.8% and incident DNP in 21%. Similar to other stud-
ies, advancing age and height were important risk factors
for worsening of both DSP and DNP.1,13-18 Opiates were
more frequently used by individuals with DNP. Other
studies have shown that DNP contributes to the burden
of polypharmacy in older PWH.19 Anticonvulsants,
Figure 2. Univariate baseline predictors of incident DNP. DSP, distal sensory polyneuropathy; BMI, body mass index. D-drug, neurotoxic
nucleoside antiretroviral – zalcitabine (ddC), didanosine (ddI), or stavudine (d4T).
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antidepressants, topical agents, and nonspecific analgesics
may help relieve neuropathic pain, but their use is associ-
ated with drug-drug interactions and substantial adverse
side effects such as cognitive impairment.
DNP was closely related to depressed mood, particu-
larly MDD. We and others have observed this previ-
ously.20-22 It is not clear whether treating depression can
ameliorate DNP or vice-versa, but this issue deserves
exploration.
At the same time, substantial numbers of aging PWH
remained free of DNP and disability. Some others
improved, despite clear evidence of DSP on careful physi-
cal examination. Protective factors with respect to DNP
included employment and lower BMI. It is not clear why
employment was protective, but perhaps it is a surrogate
for other, unmeasured factors such as better overall health
status. Additionally, BMI may be a surrogate for vascular
risk factors that may contribute to peripheral nerve
injury.23-26 Also, some individuals with DSP at baseline
improved at 12 years. These results suggest partial
reversibility of the neuropathy phenotype, and raise hope
for the promise of therapies designed to promote neu-
roregeneration. For example, Calcutt et al recently made
the novel observation that dermal muscarinic M3 recep-
tors suppress regeneration of the epidermal nerve fiber
layer, and that blockade of these receptors could restore
the regenerative capacity of these fibers.27 In addition, a
recent Cochrane review28 showed that acetyl-L-carnitine
treatment produced a significant pain reduction with
respect to baseline and showed beneficial effects on nerve
conduction parameters and nerve fiber regeneration.
DNP was a predictor of incident DSP, suggesting that
DNP is an early or subclinical manifestation of DSP. We
have previously shown that the presence of DNP has high
sensitivity for DSP on more comprehensive neuropathy
evaluations, even in those for whom DSP is not found on
routine clinical examination.29 Thus, DNP, even in the
absence of clinically documented DSP, may be used to
identify individuals in whom neuroregenerative therapies
might be most effective.
Before the introduction of ART, HIV neuropathy was
closely associated with advanced immunosuppression,
which is reflected in a lower current CD4 count and a
higher viral load. In contrast, our findings in an ART-
treated cohort, similar to others,13,17 show that that these
factors are no longer associated with neuropathy or neu-
ropathic pain. At the same time, ART has been associated
with the development of DSP symptoms in some individ-
uals despite reducing viral load.30,31 Studies using animal
models exposed to tenofovir disoproxil fumarate support
a role for ART in DSP.32 However, more work is needed
to understand how DSP manifests despite reduced viral
loads.
Limitations of this study include potential bias due to
selective loss to follow-up of participants from death or
inability to return for research evaluations. We believe
this is more likely to affect those with DSP and DNP, and
thus represents a conservative bias. Our cohort may not
be representative of the larger population of PWH. In
particular, although rates of viral suppression increased
very much from baseline to follow-up, those rates were
still lower than in many other cohorts. The number of
women was relatively small, limiting any conclusions
regarding sex differences.
A better understanding of risk factors for incident and
worsening neuropathy and neuropathic symptoms are will
promote the development of preventative strategies such
as neuroprotective and neuroregenerative agents and life-
style changes. Our findings suggest that obesity and
unemployment may increase the risk of developing DSP.
Figure 3. Distal neuropathic pain at 12 years was associated with poorer quality of life as measured by the MOS-HIV Physical and Mental Health
Summary Scores.
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